Why did AbbVie (NYSE:ABBV) lower its 2026 profit guidance?

AbbVie (NYSE:ABBV) lowered its adjusted EPS outlook to $13.87–$14.07 due mainly to the expected $0.14 per share earnings impact from its Apogee Therapeutics acquisition.

Which AbbVie (NYSE:ABBV) drugs drove Q2 2026 growth?

AbbVie (NYSE:ABBV) growth was driven by Skyrizi, which generated $5.51 billion in revenue, and Rinvoq, which generated $2.53 billion.

How did Humira sales perform for AbbVie (NYSE:ABBV)?

AbbVie (NYSE:ABBV) reported global Humira sales of $756 million in Q2 2026, down 36% year over year due to biosimilar competition.

What is the Apogee Therapeutics acquisition?

AbbVie (NYSE:ABBV) agreed to acquire Apogee Therapeutics for approximately $10.9 billion, gaining access to zumilokibart, a drug candidate targeting atopic dermatitis and asthma.

Image for illustrative purposes only. Not a real photo.

AbbVie posts robust Q2 results as revenue reaches $17B

Written by Isaac FrancisPublished Jul 31, 2026, 1:52 PM

AbbVie reported second-quarter 2026 revenue of $16.99 billion, up 10% year over year.
Adjusted EPS of $3.65 exceeded analyst expectations, but full-year profit guidance was lowered due to the Apogee acquisition.
Skyrizi and Rinvoq delivered strong growth, offsetting continued Humira declines.

AbbVie (NYSE:ABBV) reported second-quarter 2026 revenue of $16.99 billion, up 10% year over year, with adjusted earnings per share of $3.65, exceeding analyst expectations of $3.60.

The company lowered its full-year 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11, reflecting the expected $0.14 per share impact from its planned acquisition of Apogee Therapeutics.

Immunology products continued to drive growth, with Skyrizi revenue increasing 24.4% to $5.51 billion and Rinvoq revenue rising 24.5% to $2.53 billion.

AbbVie’s immunology portfolio generated $8.79 billion in quarterly revenue, up 15% year over year.

AbbVie’s neuroscience segment also performed strongly, with revenue increasing 20% to $3.23 billion, while Humira global sales declined 36% to $756 million due to biosimilar competition.

The company agreed to acquire Apogee Therapeutics for approximately $10.9 billion, with the deal centered on zumilokibart, a next-generation treatment candidate for moderate-to-severe atopic dermatitis and asthma.

The Apogee acquisition represents AbbVie’s largest acquisition in more than five years as the company continues using strategic deals to strengthen its pipeline and offset the impact of Humira’s declining market exclusivity.